Patents by Inventor Wenqi Hu

Wenqi Hu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240084027
    Abstract: Disclosed is a multi-specific antibody targeting CD40 and PD-L1, as well as its use in the treatment of diseases such as tumors.
    Type: Application
    Filed: August 15, 2023
    Publication date: March 14, 2024
    Inventors: Jiangmei LI, Xuechen ZHOU, Wenqi HU, Feng LI
  • Publication number: 20230382995
    Abstract: Disclosed is a molecule, e.g., a single-domain antibody, or a heavy chain only antibody, that specifically binds human PD-LI, and its use in treating diseases such as tumors.
    Type: Application
    Filed: May 25, 2023
    Publication date: November 30, 2023
    Inventors: Xuechen ZHOU, Guangzhong LIN, Jiangmei LI, Wenqi HU, Feng LI
  • Publication number: 20230348612
    Abstract: Disclosed is a single chain fragment variable (scFv), comprising a heavy chain variable region, a linker and a ? light chain variable region, wherein the ? light chain variable region is engineered to comprise leucin (L), threonine (T) and alanine (A) at Position 104 to 106 according to the Kabat numbering scheme.
    Type: Application
    Filed: April 26, 2023
    Publication date: November 2, 2023
    Inventors: Guangzhong LIN, Jiangmei LI, Wenqi HU, Feng LI
  • Publication number: 20230348629
    Abstract: Disclosed is a bispecific molecule specifically binding TIGIT and VEGF, and its use in treatment of e.g., tumors.
    Type: Application
    Filed: April 26, 2023
    Publication date: November 2, 2023
    Inventors: Jiangmei LI, Wenqi HU, Feng LI
  • Publication number: 20230348630
    Abstract: Disclosed is a monoclonal antibody that specifically binds BCMA, or an antigen binding fragment thereof, and its use in treating cancers such as multiple myeloma. Also disclosed is a monoclonal antibody that specifically binds CD3, or an antigen binding fragment thereof, and its use in treating or alleviating an inflammatory disease, an autoimmune disease, or transplantation rejection. Further disclosed is an anti-BCMA/CD3 bispecific antibody, and its use in treating diseases such as cancers.
    Type: Application
    Filed: April 26, 2023
    Publication date: November 2, 2023
    Inventors: Fangjie LIU, Jiangmei LI, Wenqi HU, Feng LI
  • Publication number: 20230332901
    Abstract: A method of re-routing an off route vehicle is described. A transportation system provides a route from an origin to a destination to a client device associated with a driver of the route. The transportation system receives location data from the client device associated with the driver and calculates one or more error values based on the location data. The transportation system provides a re-route to the client device based on determining that the one or more error values are greater than a threshold value.
    Type: Application
    Filed: April 18, 2022
    Publication date: October 19, 2023
    Inventors: Shaishav Gandhi, Jordan Ponce, Anjini Shukla, Roberto Fonti, Qianyu Xu, Wenqi Hu, Dylan Babbs, Pushkar Prateek, Jasvinder Singh, Yi Lu, Junzhuo Chen
  • Publication number: 20230320801
    Abstract: The invention relates to a tube (100) with a hollow cylindrical elastic base structure (102) for insertion into a blood vessel (200) of a vascular system (202). The tube (100) comprises an outer anisotropic surface structure (104) comprising a geometrical anisotropy between a direction circumferential to the tube and a direction longitudinal to the tube (100). The anisotropic surface structure (104) is configured for establishing an anisotropic friction between the anisotropic surface structure (104) and an inner surface of the blood vessel (200). The anisotropic friction results in a surface propulsion of the tube (100), when the tube (100) is rotated around a central longitudinal body axis (106) of the tube (100). The tube (100) further comprises a magnetic material (108) distributed circumferentially around the tube (100) and configured for establishing within an external magnetic field a rotation of the tube (100) around the central longitudinal body axis (106) of the tube (100).
    Type: Application
    Filed: April 11, 2023
    Publication date: October 12, 2023
    Inventors: Tianlu WANG, Wenqi HU, Metin SITTI
  • Publication number: 20230286048
    Abstract: The present invention relates to a method of fabricating magnetic deformable machines comprising heterogeneous voxels, as well as to a deformable 3D magnetic machine, the magnetic machine having a size of less than 10000 mm, the magnetic machine comprising a plurality of voxels of which at least some are magnetic, with at least some of the voxels having a Young's modulus of less than 500 MPa, the plurality of voxels being bonded one to another with a bonding agent, wherein each voxel is of predefined shape, size, has predefined magnetic properties and predefined material properties.
    Type: Application
    Filed: August 4, 2021
    Publication date: September 14, 2023
    Inventors: Jiachen Zhang, Ziyu Ren, Wenqi Hu, Metin Sitti
  • Publication number: 20230249182
    Abstract: A microfluidic chip device based on a magnetic field-controlled fluorescently labeled cell sorting method and a use method are disclosed. The microfluidic chip comprises a sample channel, two sheath fluid channels, a first fluorescence detection area, a second fluorescence detection area, a magnetic field control system, a magnetic field-controlled cell sorting area, a target cell channel, and a waste fluid channel. Based on fluorescence signals labeled on the cells, the FACS system is combined with a magnetic field-controlled sorting system to achieve automated cell sorting, which not only miniaturizes and automates the sorting detection integration, but also has the advantages of easy and economical operation. The device sorts both a large number of cell samples and a small number of cell samples, thus overcoming the defects of a flow cytometer.
    Type: Application
    Filed: September 1, 2022
    Publication date: August 10, 2023
    Applicant: NANTONG UNIVERSITY
    Inventors: Yuling QIN, Huanhuan CHEN, Tianzhi MAO, Wenqi HU, Lvyang ZHU, Qu TANG
  • Patent number: 11718674
    Abstract: An isolated monoclonal antibody, or an antigen-binding portion thereof, that specifically binds human PD0-L1. A nucleic acid molecule encoding the antibody or antigen-binding portion thereof, an expression vector, a host cell and a method for expressing the antibody or antigen-binding portion thereof are also provided. The present disclosure further provides an immuneconjugate, a bispecific molecule, a chimeric antigen receptor, an oncolytic virus and a pharmaceutical composition comprising the antibody or antigen-binding portion thereof, as well as a treatment method using the antibody or antigen-binding portion thereof.
    Type: Grant
    Filed: August 30, 2021
    Date of Patent: August 8, 2023
    Assignee: BEIJING MABWORKS BIOTECH CO., LTD.
    Inventors: Jiangmei Li, Wenqi Hu, Feng Li
  • Publication number: 20220396617
    Abstract: An isolated monoclonal antibody, or an antigen-binding portion thereof, that specifically binds human TIGIT. A nucleic acid molecule encoding the antibody or antigen-binding portion thereof, an expression vector, a host cell and a method for expressing the antibody or antigen-binding portion thereof are also provided. The present disclosure further provides an immunoconjugate, a bispecific molecule, a chimeric antigen receptor, an oncolytic virus and a pharmaceutical composition comprising the antibody or antigen-binding portion thereof, as well as a treatment method using the antibody or antigen-binding portion thereof.
    Type: Application
    Filed: August 30, 2021
    Publication date: December 15, 2022
    Inventors: Jiangmei LI, Wenqi HU, Feng LI
  • Publication number: 20220298244
    Abstract: An isolated monoclonal antibody, or an antigen-binding portion thereof, that specifically binds human PD-L1. A nucleic acid molecule encoding the antibody or antigen-binding portion thereof, an expression vector, a host cell and a method for expressing the antibody or antigen-binding portion thereof are also provided. The present disclosure further provides an immuneconjugate, a bispecific molecule, a chimeric antigen receptor, an oncolytic virus and a pharmaceutical composition comprising the antibody or antigen-binding portion thereof, as well as a treatment method using the antibody or antigen-binding portion thereof.
    Type: Application
    Filed: August 30, 2021
    Publication date: September 22, 2022
    Inventors: Jiangmei LI, Wenqi HU, Feng LI
  • Publication number: 20210398041
    Abstract: A coordination server receives a request from a client device of a rider for transportation from a first location. The coordination server identifies a frequent spot based on the first location. The frequent spot is associated with a particular location and represents a plurality of historic first locations within a threshold distance from the frequent spot. The coordination server identifies a closest road segment with respect to the frequent spot. The closest road segment is a road segment of a plurality of road segments of an electronic map representing a geographic area around the first location. The coordination server determines a pickup side of the closest road segment based on the first location and the closest road segment. The coordination server sends, to a client device of a driver, a route to the first location such that the driver arrives on the pickup side of the closest road segment.
    Type: Application
    Filed: June 21, 2021
    Publication date: December 23, 2021
    Inventors: Shivendra Pratap Singh, Krishna Aditya Gabbita, Yuxing Zhang, Konstantin Stulov, Pranav Deepak Agrawal, Vivek Sankaravadivel, Saandeep Depatla, Zehao Hu, Wenqi Hu, Andrew Irish, Anand Karthik Tumuluru, Henri Lapierre, Pranit Arora
  • Patent number: 11091558
    Abstract: An isolated monoclonal antibody or an antigen-binding portion thereof that specifically binds human OX40. A nucleic acid molecule encoding the antibody, an expression vector, a host cell and a method for expressing the antibody are also provided. The present invention further provides an immunoconjugate, a bispecific molecule, a chimeric antigen receptor, an oncolytic virus and a pharmaceutical composition comprising the antibody, as well as a treatment method using an anti-OX40 antibody of the invention.
    Type: Grant
    Filed: October 14, 2019
    Date of Patent: August 17, 2021
    Assignee: BEIJING MABWORKS BIOTECH CO. LTD.
    Inventors: Wenqi Hu, Jiangmei Li, Lun Jiang, Feng Li
  • Patent number: 11031160
    Abstract: The present invention relates to a method of actuating a shape changeable member of actuatable material. The invention further relates to a shape changeable member and to a system comprising such a shape changeable member and a magnetic field apparatus.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: June 8, 2021
    Inventors: Wenqi Hu, Guo Zhan Lum, Massimo Mastrangeli, Metin Sitti
  • Patent number: 10946092
    Abstract: An isolated monoclonal antibody or an antigen-binding portion thereof that specifically binds human LAG3. A nucleic acid molecule encoding the antibody or antigen-binding portion thereof, an expression vector, a host cell and a method for expressing the antibody or antigen-binding portion thereof are also provided. The present disclosure further provides an immuneconjugate, a bispecific molecule, a chimeric antigen receptor, and a pharmaceutical composition comprising the antibody or antigen-binding portion thereof thereof, as well as a treatment method using the same.
    Type: Grant
    Filed: August 3, 2020
    Date of Patent: March 16, 2021
    Assignees: BEIJING MABWORKS BIOTECH CO., LTD., BEIJING MABRIDGE BIOPHARMACEUTICAL CO., LTD.
    Inventors: Wenqi Hu, Jiangmei Li, Feng Li
  • Publication number: 20200231692
    Abstract: An isolated monoclonal antibody or an antigen-binding portion thereof that specifically binds human OX40. A nucleic acid molecule encoding the antibody, an expression vector, a host cell and a method for expressing the antibody are also provided. The present invention further provides an immunoconjugate, a bispecific molecule, a chimeric antigen receptor, an oncolytic virus and a pharmaceutical composition comprising the antibody, as well as a treatment method using an anti-OX40 antibody of the invention.
    Type: Application
    Filed: October 14, 2019
    Publication date: July 23, 2020
    Inventors: Wenqi HU, Jiangmei Li, Lun Jiang, Feng Li
  • Patent number: 10662249
    Abstract: An isolated monoclonal antibody that specifically binds human CD40. A nucleic acid molecule encoding the antibody, an expression vector, a host cell and a method for expressing the antibody are also provided. The present invention further provides an immunoconjugate, a bispecific molecule, a chimeric antigen receptor, an oncolytic virus and a pharmaceutical composition comprising the antibody, as well as a treatment method using an anti-CD40 antibody of the invention.
    Type: Grant
    Filed: December 23, 2019
    Date of Patent: May 26, 2020
    Assignees: BEIJING MABWORKS BIOTECH CO., LTD., BEIJING MABRIDGE BIOPHARMACEUTICAL CO., LTD.
    Inventors: Wenqi Hu, Jiangmei Li, Feng Li
  • Patent number: 10654937
    Abstract: An isolated monoclonal antibody that specifically binds human CD40. A nucleic acid molecule encoding the antibody, an expression vector, a host cell and a method for expressing the antibody are also provided. The present invention further provides an immunoconjugate, a bispecific molecule, a chimeric antigen receptor, an oncolytic virus and a pharmaceutical composition comprising the antibody, as well as a treatment method using an anti-CD40 antibody of the invention.
    Type: Grant
    Filed: December 23, 2019
    Date of Patent: May 19, 2020
    Assignees: BEIJING MABWORKS BIOTECH CO., LTD., BEIJING MABRIDGE BIOPHARMACEUTICAL CO., LTD.
    Inventors: Wenqi Hu, Jiangmei Li, Feng Li
  • Patent number: 10654939
    Abstract: An isolated monoclonal antibody that specifically binds human CD40. A nucleic acid molecule encoding the antibody, an expression vector, a host cell and a method for expressing the antibody are also provided. The present invention further provides an immunoconjugate, a bispecific molecule, a chimeric antigen receptor, an oncolytic virus and a pharmaceutical composition comprising the antibody, as well as a treatment method using an anti-CD40 antibody of the invention.
    Type: Grant
    Filed: December 23, 2019
    Date of Patent: May 19, 2020
    Assignees: BEIJING MABWORKS BIOTECH CO., LTD., BEIJING MABRIDGE BIOPHARMACEUTICAL CO., LTD.
    Inventors: Wenqi Hu, Jiangmei Li, Feng Li